• CIE11: https://icd.who.int/browse11/l-m/en INTERNATIONAL CLASSIFICATION OF DISEASES – ICD-11 for Mortality and Morbidity Statistics. Cap 18.

• Guía Técnica Nacional para la Estandarización del Procedimiento de la Atención Integral de la Gestante en la Interrupción Voluntaria por Indicación Terapéutica del embarazo menor de 22 semanas con consentimiento informado en el marco de lo dispuesto en el artículo 119° del código penal. MINSA 2016

• Guías De Práctica Clínica Y De Procedimientos En Obstetricia Y Perinatología. MINSA. Instituto Nacional Materno Perinatal. 2010. http://bvs.minsa.gob.pe/local/MINSA/3318.pdf 
• Report. World Health organization. Consultations on Definitions and Standards related to Maternal and Child health and the Perinatal Period. Washington DC USA. 30 March to3 April 1987.
• Glosario de terminología en Técnicas de Reproducción Asistida (TRA). Versión revisada y reparada por el International Committee for Monitoring Assisted Reproductive Technology (ICMART) y la Organización Mundial de la Salud (OMS).  F. Zegers-Hochschild,a G. D. Adamson,b J. de Mouzon,c O. Ishihara,d R. Mansour,e K. Nygren,f E. Sullivan,g and S. Vanderpoel,h for ICMART and WHO a Unit of Reproductive Medicine, Clinicas las Condes, Santiago, Chile; b Fertility Physicians of Northern California, Palo Alto and San Jose, California; c INSERM U822,H^opital de Bic^etre, Le Kremlin Bic^etre Cedex, Paris, France; d Saitama Medical University Hospital, Moroyama, Saitana, Japan; e Cairo, Egypt; f IVF Unit, Sophiahemmet Hospital, Stockholm, Sweden; g Perinatal and Reproductive Epidemiology and Research Unit, School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia; and h Department of Reproductive Health and Research and the Special Program of Research, Development, and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland.

• Allen, R., & O’Brien, B. M. (2009). Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics & gynecology, 2(3), 159–168.
• Zieman, M., Fong, S. K., Benowitz, N. L., Banskter, D., & Darney, P. D. (1997). Absorption kinetics of misoprostol with oral or vaginal administration. Obstetrics and gynecology, 90(1), 88–92. https://doi.org/10.1016/S0029-7844(97)00111-7
• Aronsson, A., Bygdeman, M., & Gemzell-Danielsson, K. (2004). Effects of misoprostol on uterine contractility following different routes of administration. Human reproduction (Oxford, England), 19(1), 81–84. https://doi.org/10.1093/humrep/deh005
• Baskett T. F. (2003). The development of prostaglandins. Best practice & research. Clinical obstetrics & gynaecology, 17(5), 703–706. https://doi.org/10.1016/s1521-6934(03)00048-8
• Bygdeman M. (2003). Pharmacokinetics of prostaglandins. Best practice & research. Clinical obstetrics & gynaecology, 17(5), 707–716. https://doi.org/10.1016/s1521-6934(03)00043-9
• Cicinelli, E., de Ziegler, D., Bulletti, C., Matteo, M. G., Schonauer, L. M., & Galantino, P. (2000). Direct transport of progesterone from vagina to uterus. Obstetrics and gynecology, 95(3), 403–406. https://doi.org/10.1016/s0029-7844(99)00542-6
• Olson D. M. (2003). The role of prostaglandins in the initiation of parturition. Best practice & research. Clinical obstetrics & gynaecology, 17(5), 717–730. https://doi.org/10.1016/s1521-6934(03)00069-5
• Berer, M. (2005). Why Medical Abortion Is Important for Women. Reproductive Health Matters, 13(26), 6–10. http://www.jstor.org/stable/3776469
• Berer, M. (2005). Medical Abortion: A Fact Sheet. Reproductive Health Matters, 13(26), 20–24. http://www.jstor.org/stable/3776472
• Faúndes, A., Fiala, C., Tang, O. S., & Velasco, A. (2007). Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S172–S177. https://doi.org/10.1016/j.ijgo.2007.09.006
• Allen, R., & O’Brien, B. M. (2009). Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics & gynecology, 2(3), 159–168.
• Tang, O. S., Gemzell-Danielsson, K., & Ho, P. C. (2007). Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S160–S167. https://doi.org/10.1016/j.ijgo.2007.09.004 
• Tang, O. S., Schweer, H., Lee, S. W., & Ho, P. C. (2009). Pharmacokinetics of repeated doses of misoprostol. Human reproduction (Oxford, England), 24(8), 1862–1869. https://doi.org/10.1093/humrep/dep108
• WHO model list of essential medicines (20th List). March 2017 (Amended August 2017). Ginebra: Organización Mundial de la Salud; 2017 (http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf, consultado el 28 DE DICIEMBRE DE 2021).
• Tang, J., Kapp, N., Dragoman, M., & de Souza, J. P. (2013). WHO recommendations for misoprostol use for obstetric and gynecologic indications. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 121(2), 186–189. https://doi.org/10.1016/j.ijgo.2012.12.009

• WHO Library Cataloguing-in-Publication Data Safe abortion: technical and policy guidance for health systems – 2 nd  ed. 1.Abortion, Induced – methods 2.Abortion, Induced – standards. 3.Prenatal care  organization and administration 4.Prenatal care – standards  5.Maternal welfare 6.Health policy 7.Guidelines. I.World Health Organization. ISBN 978 92 4 154843 4 . (NLM classification: WQ 440) © World Health Organization 2012.
• Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (http://www​.who.int/reproductivehealth​/publications​/unsafe_abortion​/9789241548434/en/, accessed 17 October 2018).
• Tratamiento médico del aborto. Ginebra: Organización Mundial de la Salud; 2018. Licencia: CC BY-NC-SA 3.0 IGO. Catalogación (CIP): Puede consultarse en http://apps.who.int/iris.
• Morris, J. L., Winikoff, B., Dabash, R., Weeks, A., Faundes, A., Gemzell-Danielsson, K., Kapp, N., Castleman, L., Kim, C., Ho, P. C., & Visser, G. (2017). FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 138(3), 363–366. https://doi.org/10.1002/ijgo.12181
• Tang, J., Kapp, N., Dragoman, M., & de Souza, J. P. (2013). WHO recommendations for misoprostol use for obstetric and gynecologic indications. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 121(2), 186–189. https://doi.org/10.1016/j.ijgo.2012.12.009
• Rowlands S. (2011). Misinformation on abortion. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 16(4), 233–240. https://doi.org/10.3109/13625187.2011.570883
• Allen, R., & O’Brien, B. M. (2009). Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics & gynecology, 2(3), 159–168. 
• Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., Chami, S., … Carbonell, J. L. L. (2000). Misoprostol for abortion up to 9 weeks’ gestation in adolescents. The European Journal of Contraception and Reproductive Health Care, 5, 227-233.
• Carbonell Esteve, J. L., Varela, L., Velazco, A., Cabezas, E., Tanda, R. y Sanchez, C. (1998). Vaginal misoprostol for late first trimester abortion. Contraception, 57(5), 329-333. Carbonell, J. L., Varela, L., Velazco, A., Tanda, R. y Sanchez, C. (1999). Vaginal misoprostol for abortion at 10-13 weeks’ gestation. The European Journal of Contraception and Reproductive Health Care, 4(1), 35-40. 
• Carbonell, J. L., Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S. y Mari, J. (2001). Misoprostol for abortion at 9-12 weeks’ gestation in adolescents. The European Journal of Contraception and Reproductive Health Care, 6(1), 39-45. 
• Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2019). Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstetrics and gynecology, 133(1), 137–147. https://doi.org/10.1097/AOG.0000000000003017 von Hertzen, H., Piaggio, G., Huong, N. T., Arustamyan, K., Cabezas, E., Gomez, M., Khomassuridze, A., Shah, R., Mittal, S., Nair, R., Erdenetungalag, R., Huong, T. M., Vy, N. D., Phuong, N. T., Tuyet, H. T., Peregoudov, A., & WHO Research Group on Postovulatory Methods of Fertility Regulation (2007). Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet (London, England), 369(9577), 1938–1946. https://doi.org/10.1016/S0140-6736(07)60914-3 
• Tang, J., Kapp, N., Dragoman, M., & de Souza, J. P. (2013). WHO recommendations for misoprostol use for obstetric and gynecologic indications. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 121(2), 186–189. https://doi.org/10.1016/j.ijgo.2012.12.009

Kulier, R., Kapp, N., Gülmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. The Cochrane database of systematic reviews, 2011(11), CD002855. https://doi.org/10.1002/14651858.CD002855.pub4

• WHO Library Cataloguing-in-Publication Data Safe abortion: technical and policy guidance for health systems – 2 nd  ed. 1.Abortion, Induced – methods 2.Abortion, Induced – standards. 3.Prenatal care  organization and administration 4.Prenatal care – standards  5.Maternal welfare 6.Health policy 7.Guidelines. I.World Health Organization. ISBN 978 92 4 154843 4 . (NLM classification: WQ 440) © World Health Organization 2012.
• Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (http://www​.who.int/reproductivehealth​/publications​/unsafe_abortion​/9789241548434/en/, accessed 17 October 2018).
• Tratamiento médico del aborto. Ginebra: Organización Mundial de la Salud; 2018. Licencia: CC BY-NC-SA 3.0 IGO. Catalogación (CIP): Puede consultarse en http://apps.who.int/iris. 
• Erdman, J. N., DePiñeres, T., & Kismödi, E. (2013). Updated WHO guidance on safe abortion: health and human rights. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 120(2), 200–203. https://doi.org/10.1016/j.ijgo.2012.10.009
• Aborto Con Misoprostol Autoadministrado: Una Guía Para Las Mujeres. International Women’s Health Coalition • Gynuity Health Projects
• Faúndes, A., Fiala, C., Tang, O. S., & Velasco, A. (2007). Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S172–S177. https://doi.org/10.1016/j.ijgo.2007.09.006
• Allen, R., & O’Brien, B. M. (2009). Uses of misoprostol in obstetrics and gynecology. Reviews in obstetrics & gynecology, 2(3), 159–168. [Rev Obstet Gynecol. 2009;2(3):159-168 doi:10.3909/riog0055 
• Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2019). Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstetrics and gynecology, 133(1), 137–147. https://doi.org/10.1097/AOG.0000000000003017
• Fekih, M., Fathallah, K., Ben Regaya, L., Bouguizane, S., Chaieb, A., Bibi, M., & Khairi, H. (2010). Sublingual misoprostol for first trimester termination of pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 109(1), 67–70. https://doi.org/10.1016/j.ijgo.2009.11.008 
• Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., Chami, S., … Carbonell, J. L. L. (2000). Misoprostol. for abortion up to 9 weeks’ gestation in adolescents. The European Journal of Contraception and Reproductive. Health Care, 5, 227-233. 
• Carbonell Esteve, J. L., Varela, L., Velazco, A., Cabezas, E., Tanda, R. y Sanchez, C. (1998). Vaginal misoprostol for late first trimester abortion. Contraception, 57(5), 329-333. 
• Carbonell, J. L., Varela, L., Velazco, A., Tanda, R. y Sanchez, C. (1999). Vaginal misoprostol for abortion at 10-13 weeks’ gestation. The European Journal of Contraception and Reproductive Health Care, 4(1), 35-40. 
• Carbonell, J. L., Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S. y Mari, J. (2001). Misoprostol for abortion at 9-12 weeks’ gestation in adolescents. The European Journal of Contraception and Reproductive Health Care, 6(1), 39-45. 
• Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2019). Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstetrics and gynecology, 133(1), 137–147. https://doi.org/10.1097/AOG.0000000000003017
• Tang, O. S., Schweer, H., Lee, S. W., & Ho, P. C. (2009). Pharmacokinetics of repeated doses of misoprostol. Human reproduction (Oxford, England), 24(8), 1862–1869. https://doi.org/10.1093/humrep/dep108 
• Von Hertzen, H., Piaggio, G., Huong, N. T., Arustamyan, K., Cabezas, E., Gomez, M., Khomassuridze, A., Shah, R., Mittal, S., Nair, R., Erdenetungalag, R., Huong, T. M., Vy, N. D., Phuong, N. T., Tuyet, H. T., Peregoudov, A., & WHO Research Group on Postovulatory Methods of Fertility Regulation (2007). Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet (London, England), 369(9577), 1938–1946. https://doi.org/10.1016/S0140-6736(07)60914-3 
• Tratamiento médico del aborto. Ginebra: Organización Mundial de la Salud; 2018. Licencia: CC BY-NC-SA 3.0 IGO. 
• Tang, J., Kapp, N., Dragoman, M., & de Souza, J. P. (2013). WHO recommendations for misoprostol use for obstetric and gynecologic indications. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 121(2), 186–189. https://doi.org/10.1016/j.ijgo.2012.12.009 
• Abubeker, Ferid,   Lavelanet, Antonella et al. BMC Women’s Health (2020) 20:142. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. ) 20:142. https://doi.org/10.1186/s12905-020-01003-8 
• Organización Mundial de la Salud. (2018). Medical Management of Abortion. Ginebra, Suiza: Organización Mundial de la Salud.
• Kulier, R., Kapp, N., Gülmezoglu, A. M., Hofmeyr, G. J., Cheng, L., & Campana, A. (2011). Medical methods for first trimester abortion. Cochrane Database of Systematic Reviews. doi.org/10.1002/14651858.cd002855.pub4
• Kapp, N., Eckersberger, E., Lavelanet, A., & Rodriguez, M. I. (2019). Medical abortion in the late first trimester: a systematic review. Contraception, 99(2), 77–86. https://doi.org/10.1016/j.contraception.2018.11.002

Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2019). Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstetrics and gynecology, 133(1), 137–147. https://doi.org/10.1097/AOG.0000000000003017

• Mifepristona y misoprostol en seis países de América Latina: procesos de registro y disponibilidad. Enero 2017. Lima, Perú. https://clacaidigital.info/handle/123456789/1000 
• Observatorio Peruano de Productos Farmacéuticos. SISTEMA NACIONAL DE INFORMACIÓN DE PRECIOS DE PRODUCTOS FARMACÉUTICOS – SNIPPF. http://opm.digemid.minsa.gob.pe/#/consulta-producto
• Documento Tecnico. Petitorio Nacional Unico de Medicamentos Esenciales para el Sector Salud. 2018. https://www.digemid.minsa.gob.pe/UpLoad/UpLoaded/PDF/Normatividad/2018/RM_1361-2018.pdf

• Cavieres, María Fernanda. (2011). Toxicidad del misoprostol sobre la gestación: Revisión de la literatura. Revista médica de Chile, 139(4), 516-523. https://dx.doi.org/10.4067/S0034-98872011000400015
• Aborto Seguro con Misoprostol. IPAS. Noviembre 2020. https://ipasmexico.org/2020/11/03/aborto-seguro-con-misoprostol-2/
• Moseson Heidi, Jayaweera Ruvani et al.  Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls. Articlese106 Vol10 January 2022. www.thelancet.com/lancetgh 
• Ipas. (2021). Medication Abortion Self-Care: A guide for community accompaniment to support
• women. Chapel Hill, NC: Ipas
• Moseson, H., Jayaweera, R., Raifman, S., Keefe-Oates, B., Filippa, S., Motana, R., Egwuatu, I., Grosso, B., Kristianingrum, I., Nmezi, S., Zurbriggen, R., & Gerdts, C. (2020). Self-managed medication abortion outcomes: results from a prospective pilot study. Reproductive health, 17(1), 164. https://doi.org/10.1186/s12978-020-01016-4
• Eficacia y seguridad del fármaco. Por Shalini S. Lynch , PharmD, University of California, San Francisco School of Pharmacy. Última modificación del contenido jun. 2019. Manual MSD. Versión para profesionales. Rev.28ene2021 https://www.msdmanuals.com/es/professional/farmacolog%C3%ADa-cl%C3%ADnica/conceptos-farmacoterap%C3%A9uticos/eficacia-y-seguridad-del-f%C3%A1rmaco
• Von Hertzen, H., Piaggio, G., Huong, N. T., Arustamyan, K., Cabezas, E., Gomez, M., Khomassuridze, A., Shah, R., Mittal, S., Nair, R., Erdenetungalag, R., Huong, T. M., Vy, N. D., Phuong, N. T., Tuyet, H. T., Peregoudov, A., & WHO Research Group on Postovulatory Methods of Fertility Regulation (2007). Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet (London, England), 369(9577), 1938–1946. https://doi.org/10.1016/S0140-6736(07)60914-3
• Faúndes, A., Fiala, C., Tang, O. S., & Velasco, A. (2007). Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S172–S177. https://doi.org/10.1016/j.ijgo.2007.09.006
• Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2019). Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstetrics and gynecology, 133(1), 137–147. https://doi.org/10.1097/AOG.0000000000003017
• Tang, O. S., Gemzell-Danielsson, K., & Ho, P. C. (2007). Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S160–S167. https://doi.org/10.1016/j.ijgo.2007.09.004
• Tang, O. S., Schweer, H., Lee, S. W., & Ho, P. C. (2009). Pharmacokinetics of repeated doses of misoprostol. Human reproduction (Oxford, England), 24(8), 1862–1869. https://doi.org/10.1093/humrep/dep108
• Kapp, N., Eckersberger, E., Lavelanet, A., & Rodriguez, M. I. (2019). Medical abortion in the late first trimester: a systematic review. Contraception, 99(2), 77–86. https://doi.org/10.1016/j.contraception.2018.11.002

Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2019). Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstetrics and gynecology, 133(1), 137–147. https://doi.org/10.1097/AOG.0000000000003017

• https://repository.udca.edu.co/handle/11158/2873
• Reacciones adversas con Misoprostol reportadas al Programa Mundial de Farmacovigilancia de la OMS 1985-2019
• Cavieres, María Fernanda. (2011). Toxicidad del misoprostol sobre la gestación: Revisión de la literatura. Revista médica de Chile, 139(4), 516-523. https://dx.doi.org/10.4067/S0034-98872011000400015
• Da Silva, Dal Pizzol Tatiane, Vieira Sanseverino María Teresa, Serrate Sotero, Mengue. Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies. Cad. Saude Publica, Rio de Janeiro, 24(6):1447-1453, jun. 2008. https://doi.org/10.1590/S0102-311X2008000600025 
• Da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol. 2006;22(4):666-671. doi:10.1016/j.reprotox.2006.03.015
• Philip Neena M., Shannon Caitlin, Winikoff Beverly edits. 2002 Misoprostol and Teratogenicity: Reviewing the Evidence Report of a Meeting at the Population  Council. New York, New York. The Population Council Inc. Critical Issues in Reproductive Health
• https://knowledgecommons.popcouncil.org/cgi/viewcontent.cgi?article=2658&context=departments_sbsr-rh / https://gynuity.org/assets/resources/mtg_rep_miso_teratogen_sp.pdf
• Barbero P, Liascovich R, Valdez R, Moresco A. Efecto teratogénico del misoprostol: un estudio prospectivo en Argentina [Misoprostol teratogenicity: a prospective study in Argentina]. Arch Argent Pediatr. 2011;109(3):226-231. doi:10.1590/S0325-00752011000300007
• A. Pérez-Landeiro, M. A. Allende-Bandrés, M. J. Agustín Fernández, P. Palomo Palomo. Teratogénesis: clasificaciones. Revisión.  FARMACIA HOSP (Madrid). Vol. 26. N.° 3, pp. 171-177, 2002
• Tang, O. S., Gemzell-Danielsson, K., & Ho, P. C. (2007). Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S160–S167. https://doi.org/10.1016/j.ijgo.2007.09.004
• Prestación de Servicios de Aborto Con Medicamentos en Contextos de bajos recursos. Guia Introductoria. Segunda Edición. Abuabara K, Blum J, y col. Population Council and Gynuiti health Projects

• Rowlands S. (2011). Misinformation on abortion. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 16(4), 233–240. https://doi.org/10.3109/13625187.2011.570883

• Uso De Misoprostol En Obstetricia Y Ginecología. Tercera Edición. Mayo  2013. MANUAL FLASOG
• Guía Técnica Nacional para la Estandarización del Procedimiento de la Atención Integral de la Gestante en la Interrupción Voluntaria por Indicación Terapéutica del embarazo menor de 22 semanas con consentimiento informado en el marco de lo dispuesto en el artículo 119° del código penal. MINSA 2016
• Guías De Práctica Clínica Y De Procedimientos En Obstetricia Y Perinatología. MINSA. Instituto Nacional Materno Perinatal. 2010. http://bvs.minsa.gob.pe/local/MINSA/3318.pdf

• Goyal V. (2009). Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. Obstetrics and gynecology, 113(5), 1117–1123. https://doi.org/10.1097/AOG.0b013e31819dbfe2
• Cecchini, F., Tassi, A., Londero, A. P., Baccarini, G., Driul, L., & Xodo, S. (2020). First Trimester Uterine Rupture: A Case Report and Literature Review. International journal of environmental research and public health, 17(8), 2976. https://doi.org/10.3390/ijerph17082976
• Kim JO, Han JY, Choi JS, Ahn HK, Yang JH, Kang IS, Song MJ, Nava Ocampo AA. Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report. Reprod Toxicol. 2005 Nov-Dec;20(4):575-7. http://dx.doi.org/10.1016/j.reprotox.2005.04.014
• Epub 2005 Jun 27. PubMed PMID: 15982851.
• Abbas Ahmed M., Sheha Amera M. and col. First-trimester rupture of a scarred uterus after use of sublingual misoprostol: a case report. Proceedings in Obstetrics and Gynecology, 2016;6(2):5. http://ir.uiowa.edu/cgi/viewcontent.cgi?article=1317&context=pog
• Jwarah E, Greenhalf JO. Rupture of the uterus after 800 micrograms misoprostol given vaginally for termination of pregnancy. BJOG. 2000 Jun;107(6):807.  http://dx.doi.org/10.1111/j.14710528.2000.tb13346.x PubMed PMID: 10847241.  https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1471-0528.2000.tb13346.x
• Lin, C., & Raynor, B. D. (2004). Risk of uterine rupture in labor induction of patients with prior cesarean section: an inner city hospital experience. American journal of obstetrics and gynecology, 190(5), 1476–1478. https://doi.org/10.1016/j.ajog.2004.02.03 
• Daponte, A., Nzewenga, G., Dimopoulos, K. D., & Guidozzi, F. (2006). The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section. Contraception, 74(4), 324–327. https://doi.org/10.1016/j.contraception.2006.03.023
• Chen, B. A., Reeves, M. F., Creinin, M. D., Gilles, J. M., Barnhart, K., Westhoff, C., Zhang, J., & National Institute of Child Health and Human Development Management of Early Pregnancy Failure Trial (2008). Misoprostol for treatment of early pregnancy failure in women with previous uterine surgery. American journal of obstetrics and gynecology, 198(6), 626.e1–626.e6265. https://doi.org/10.1016/j.ajog.2007.11.045
• Rouzi A. A. (2003). Second-trimester pregnancy termination with misoprostol in women with previous cesarean sections. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 80(3), 317–318. https://doi.org/10.1016/s0020-7292(02)00409-5

• Barnhart K. T. (2009). Clinical practice. Ectopic pregnancy. The New England journal of medicine, 361(4), 379–387. https://doi.org/10.1056/NEJMcp0810384
• Davey A. (2006). Mifepristone and prostaglandin for termination of pregnancy: contraindications for use, reasons and rationale. Contraception, 74(1), 16–20. https://doi.org/10.1016/j.contraception.2006.03.003
• Prestación de Servicios de Aborto Con Medicamentos en Contextos de bajos recursos. Guia Introductoria. Segunda Edición. Abuabara K, Blum J, y col. Population Council and Gynuiti health Projects

• Prestación de Servicios de Aborto Con Medicamentos en Contextos de bajos recursos. Guia Introductoria. Segunda Edición. Abuabara K, Blum J, y col. Population Council and Gynuiti health Projects
• Ipas. (2021). Medication Abortion Self-Care: A guide for community accompaniment to support women. Chapel Hill, NC: Ipas

• WHO Library Cataloguing-in-Publication Data Safe abortion: technical and policy guidance for health systems – 2 nd  ed. 1.Abortion, Induced – methods 2.Abortion, Induced – standards. 3.Prenatal care  organization and administration 4.Prenatal care – standards  5.Maternal welfare 6.Health policy 7.Guidelines. I.World Health Organization. ISBN 978 92 4 154843 4 . (NLM classification: WQ 440) © World Health Organization 2012. 

• Prestación de Servicios de Aborto Con Medicamentos en Contextos de bajos recursos. Guia Introductoria. Segunda Edición. Abuabara K, Blum J, y col. Population Council and Gynuiti health Projects
• Ipas. (2021). Medication Abortion Self-Care: A guide for community accompaniment to support
• women. Chapel Hill, NC: Ipas
• Medline Plus (26 de Diciembre de 2021). National Library of Medicine. Gestational Age. https://medlineplus.gov/ency/article/002367.htm
• Naidu K, Fredlund KL. Gestational Age Assessment. [Updated 2021 Aug 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526000/
• Gestational Age. By Arcangela Lattari Balest , MD, University of Pittsburgh, School of Medicine
• Last full review/revision Apr 2021| Content last modified Apr 2021. (25 de Diciembre de 2021).  https://www.msdmanuals.com/professional/pediatrics/perinatal-problems/gestational-age
• Averbach, S., Puri, M., Blum, M., & Rocca, C. (2018). Gestational dating using last menstrual period and bimanual exam for medication abortion in pharmacies and health centers in Nepal. Contraception, 98(4), 296–300. https://doi.org/10.1016/j.contraception.2018.06.004

• WHO Library Cataloguing-in-Publication Data Safe abortion: technical and policy guidance for health systems – 2 nd ed. 1.Abortion, Induced – methods 2.Abortion, Induced – standards. 3.Prenatal care organization and administration 4.Prenatal care – standards 5.Maternal welfare 6.Health policy 7.Guidelines. I.World Health Organization. ISBN 978 92 4 154843 4 . (NLM classification: WQ 440) © World Health Organization 2012.
• Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (http://www​.who.int/reproductivehealth​/publications​/unsafe_abortion​/9789241548434/en/, accessed 17 October 2018).
• Raymond, E. G., Harrison, M. S., & Weaver, M. A. (2018). Efficacy of Misoprostol Alone for First- Trimester Medical Abortion. Obstetrics & Gynecology, 1. doi:10.1097/aog.000000000000301
• Dosificación y Margenes terapéuticos. Causa y Detección de problemas. OFARM: Vol 25 Numero 5 Mayo 2006.

• Tang, O. S., Gemzell-Danielsson, K., & Ho, P. C. (2007). Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 99 Suppl 2, S160–S167. https://doi.org/10.1016/j.ijgo.2007.09.004 
• Aborto Con Misoprostol Autoadministrado: Una Guía Para Las Mujeres. International Women’s Health Coalition • Gynuity Health Projects 
• Prestación de Servicios de Aborto Con Medicamentos en Contextos de bajos recursos. Guia Introductoria. Segunda Edición. Abuabara K, Blum J, y col. Population Council and Gynuiti health Projects
• Ipas. (2021). Medication Abortion Self-Care: A guide for community accompaniment to support
• women. Chapel Hill, NC: Ipas

• Aborto Con Misoprostol Autoadministrado: Una Guía Para Las Mujeres. International Women’s Health Coalition • Gynuity Health Projects
• Ipas. (2021). Medication Abortion Self-Care: A guide for community accompaniment to support women. Chapel Hill, NC: Ipas

• WHO Library Cataloguing-in-Publication Data Safe abortion: technical and policy guidance for health systems – 2 nd  ed. 1.Abortion, Induced – methods 2.Abortion, Induced – standards. 3.Prenatal care  organization and administration 4.Prenatal care – standards  5.Maternal welfare 6.Health policy 7.Guidelines. I.World Health Organization. ISBN 978 92 4 154843 4 . (NLM classification: WQ 440) © World Health Organization 2012.

• Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World Health Organization; 2012 (http://www​.who.int/reproductivehealth​/publications​/unsafe_abortion​/9789241548434/en/, accessed 17 October 2018).
• Tratamiento médico del aborto. Ginebra: Organización Mundial de la Salud; 2018. Licencia: CC BY-NC-SA 3.0 IGO. Catalogación (CIP): Puede consultarse en http://apps.who.int/iris.

• Aborto Con Misoprostol Autoadministrado: Una Guía Para Las Mujeres. International Women’s Health Coalition • Gynuity Health Projects 
• Ipas. (2021). Medication Abortion Self-Care: A guide for community accompaniment to support women. Chapel Hill, NC: Ipas

• WHO Library Cataloguing-in-Publication Data Safe abortion: technical and policy guidance for
  health systems – 2 nd ed. 1.Abortion, Induced – methods 2.Abortion, Induced – standards.
  3.Prenatal care organization and administration 4.Prenatal care – standards 5.Maternal welfare
  6.Health policy 7.Guidelines. I.World Health Organization. ISBN 978 92 4 154843 4 . (NLM
  classification: WQ 440) © World Health Organization 2012.
• Safe abortion: technical and policy guidance for health systems, second edition. Geneva: World
  Health Organization; 2012
  (http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/,
  accessed 17 October 2018).
• Cameron, S. T., Glasier, A., Johnstone, A., Dewart, H., & Campbell, A. (2015). Can women
  determine the success of early medical termination of pregnancy themselves? Contraception,
  91(1), 6–11. doi:10.1016/j.contraception.2014
• Clark, W., Bracken, H., Tanenhaus, J., Schweikert, S., Lichtenberg, E. S., & Winikoff, B. (2010).
  Alternatives to a Routine Follow-Up Visit for Early Medical Abortion. Obstetrics & Gynecology,
  115(2, Part 1), 264–272. doi:10.1097/aog.0b013e3181c996f
• Perriera, L. K., Reeves, M. F., Chen, B. A., Hohmann, H. L., Hayes, J., & Creinin, M. D. (2010).
  Feasibility of telephone follow-up after medical abortion. Contraception, 81(2), 143–149.
  doi:10.1016/j.contraception.2009
• Rossi, B., Creinin, M. D., & Meyn, L. A. (2004). Ability of the clinician and patient to predict the
  outcome of mifepristone and misoprostol medical abortion. Contraception, 70(4), 313–317.
  https://doi.org/10.1016/j.contraception.2004.04.005
• Actualizaciones Clínicas en Salud Reproductiva de IPAS. Rev 21febrerp2021.
  https://www.ipas.org/clinical-update/spanish/recomendaciones-para-el-aborto-antes-de-las-13-
  semanas-de-gestacion/aborto-con-medicamentos/confirmacion-de-aborto-completo/